marked.bio

PD-L1/CTLA-4 bispecific antibody ยท bispecific antibody

KN046

2 active trials across 2 of our biomarkers, targeting PD-L1 x CTLA-4. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
BRAF V600E 1 1 Phase 2
MSI-H / dMMR 1 1 Phase 2

Trials

2 of 2 trials shown

  1. KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer

    Recruiting Phase 2 Peking University Cancer Hospital & Institute Started 2023Primary completion 2026-12 NCT05985109

    KN046regorafenib

    Cohort B: pMMR/MSS mCRC with BRAF V600E mutation, who failed fluoropyrimidine, oxaliplatin, and irinotecan treatments.

    BRAF V600EStatus may be outdated, last updated 2023-10-26Colorectal Cancer

  2. KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade

    Active, not recruiting Phase 2 Peking University Cancer Hospital & Institute Started 2023Primary completion 2026-12 NCT06099821

    KN046regorafenibapatinib

    dMMR/MSI-H cancers resistant to PD1/PDL1 blockade.

    MSI-H / dMMRDigestive System Cancers